United Therapeutics Corporation
UTHR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $800 | $799 | $794 | $736 |
| % Growth | 0.1% | 0.5% | 7.9% | – |
| Cost of Goods Sold | $101 | $88 | $93 | $76 |
| Gross Profit | $699 | $711 | $702 | $660 |
| % Margin | 87.4% | 89% | 88.4% | 89.7% |
| R&D Expenses | $128 | $134 | $149 | $134 |
| G&A Expenses | $0 | $160 | $144 | $136 |
| SG&A Expenses | $183 | $191 | $170 | $163 |
| Sales & Mktg Exp. | $0 | $31 | $27 | $27 |
| Other Operating Expenses | $0 | $22 | $0 | $6 |
| Operating Expenses | $310 | $347 | $319 | $302 |
| Operating Income | $389 | $365 | $383 | $358 |
| % Margin | 48.6% | 45.6% | 48.2% | 48.6% |
| Other Income/Exp. Net | $50 | $44 | $41 | $39 |
| Pre-Tax Income | $438 | $408 | $424 | $397 |
| Tax Expense | $99 | $99 | $101 | $95 |
| Net Income | $339 | $310 | $322 | $301 |
| % Margin | 42.4% | 38.8% | 40.6% | 40.9% |
| EPS | 7.73 | 6.86 | 7.18 | 6.74 |
| % Growth | 12.7% | -4.5% | 6.5% | – |
| EPS Diluted | 7.16 | 6.41 | 6.63 | 6.19 |
| Weighted Avg Shares Out | 44 | 45 | 45 | 45 |
| Weighted Avg Shares Out Dil | 47 | 48 | 49 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $46 | $51 | $51 | $49 |
| Interest Expense | $3 | $7 | $6 | $8 |
| Depreciation & Amortization | $22 | $21 | -$35 | $20 |
| EBITDA | $463 | $437 | $383 | $424 |
| % Margin | 57.9% | 54.7% | 48.2% | 57.6% |